Eculizumab, a humanized anti-C5 antibody, is the first drug to prevent complement-mediated intravascular hemolysis in paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS). Here, C5 is linked to atypical hemolytic-uremic syndrome.